Prevalence of Fabry's Disease in a Population of Patients With Chronic

Status Completed

Clinical Trial Summary

Fabry disease is a rare inherited metabolic disorder that predominantly affects heart, kidneys and nervous system. Fabry disease has been searched in series of patients presenting different isolated signs caused by the affection of one of these organs. Acroparesthesias and chronic crises of pain of different origins are reported in the large majority of patients during the progression of the disease. Moreover, this signs are frequently inaugurating the disease. The investigators have previously performed a preliminary single-center study which permitted to identify one female patient with Fabry disease in a series of 147 consecutive patients with chronic pain tested. The investigators now propose to confirm the results of our preliminary study. The investigators plan to evaluate the prevalence of Fabry disease in a series of 1000 patients suffering from chronic pains of undetermined aetiology and consecutively recruited.

Clinical Trial Description

Fabry disease (FD) is a rare X-linked multisytemic lysosomal disorder caused by alpha-galactosidase deficiency. Globotriaosylcéramide (Gb3) deposits are observed in almost all tissues examined. Signs of the disease appear earlier and are more severe in affected males than in females. Myocardiopathy, renal failure and neurological signs including chronic pain and peripheral neuropathies are the most frequent signs. The availability of two enzymatic replacement therapies now provides a specific and effective treatment for patients. The prevalence of FD is estimated between 1/40,000 and 1/117,000. The frequency of Fabry disease has previously been estimated in several series of patients presenting one single sign, ie renal failure, hypertrophic myocardiopathy and early onset stroke. However, no data are available about the prevalence of FD in populations of patients suffering from chronic pains of unknown origin. The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). The patients in whom the diagnosis of FD is established during this study, will be call in for an additional visit in the Investigating Centre in order to confirm the diagnosis and propose suitable assessment and care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02450604
Study type	Interventional
Source	University Hospital, Bordeaux
Contact
Status	Completed
Phase	N/A
Start date	March 5, 2015
Completion date	December 15, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01659073` - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation	N/A
Recruiting	`NCT05914311` - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration	N/A
Recruiting	`NCT05422456` - The Turkish Version of Functional Disability Inventory
Enrolling by invitation	`NCT05422443` - The Turkish Version of Pain Coping Questionnaire
Completed	`NCT05057988` - Virtual Empowered Relief for Chronic Pain	N/A
Completed	`NCT04385030` - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury	N/A
Recruiting	`NCT06206252` - Can Medical Cannabis Affect Opioid Use?
Completed	`NCT05103319` - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed	`NCT03687762` - Back on Track to Healthy Living Study	N/A
Completed	`NCT04171336` - Animal-assisted Therapy for Children and Adolescents With Chronic Pain	N/A
Completed	`NCT03179475` - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury	Phase 4
Completed	`NCT03418129` - Neuromodulatory Treatments for Pain Management in TBI	N/A
Completed	`NCT03268551` - MEMO-Medical Marijuana and Opioids Study
Recruiting	`NCT06204627` - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain	N/A
Recruiting	`NCT06060028` - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain	N/A
Completed	`NCT05496205` - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers	Phase 1
Completed	`NCT00983385` - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics	Phase 3
Recruiting	`NCT05118204` - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization	Phase 4
Terminated	`NCT03538444` - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder	N/A
Not yet recruiting	`NCT05812703` - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain — DOUFABIS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms